Cannabis Science Inc. Announces Progress in Bringing the First Cannabis Based Medicine to Market
News Feb 10, 2010
Cannabis Science Inc. announces that it is finalizing agreements with suppliers, manufactures, and research institutions that it expects will close within days and weeks to come. Once these agreements are closed they will be announced along with details on how CBIS will bring its first Cannabis based pharmaceutical products to market.
“We have worked hard to get to this point and look forward to sharing the details with our shareholders in a timely fashion, and we appreciate their continued support.”
“We have worked hard to get to this point and look forward to sharing the details with our shareholders in a timely fashion, and we appreciate their continued support” stated Dr. Robert Melamede, President & CEO.
Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its cannabis based formulations for development, certain rights to manufacturing processes, and sales in each prospective jurisdiction and or country.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE